Trevena Inc (NASDAQ:TRVN) is a biopharmaceutical company committed to the delivery of working therapies to patients struggling with chronic pain. It came up with oliceridine injection which is an investigational product that helps with pain management. Today it unveils financial results for the second quarter of 2018.
An outlook into the matter
This company also spoke in relation to its pipeline of differentiated new chemical entities and oliceridine is part of them. U.S. Food and Drug Administration (FDA) will review all before it. A lot of people wait to see if the body approves the product.
The President and Chief Executive Officer of the company Maxine Gowen applauded the company for the remarkable second quarter. To this official, what really matters its Trevena’s long-term success and that is the recent results point towards that direction.
Gowen opined, “We remain confident that the oliceridine NDA remains on track for an FDA decision by the November 2, 2018 PDUFA date, and we look forward to discussing the oliceridine data at an Advisory Committee meeting, likely in October.”
Plans underway
Trevena has several plans beforehand. One of them is strengthening its own leadership team with top-notch medical and commercial hires. The business giant also seeks to secure two important ex-US licensing transactions for the new product. Carrie Bourdow might take up the CEO role, but the point of concern is whether or not he ascends to the position through a smooth transition.
Maxine Gowen despite retiring from his President and CEO role will still remain in this company’s decision making segment. The company maintains him in the Board of Directors. The Board of Directors is receives a new member as well. This is Scott Braunstein who will bring with him great leadership skills.
THE Chair of the Trevena Board of Directors Leon O. Moulder, Jr says it was a thoughtful move giving Carrie the lead role. The new official according to him brings along with him valuable experience and that will contribute to the company’s growth.
Ms. Bourdow thanked the management for the opportunity to deliver the company’s mission to come up with innovative medicines for patients.
